The role of inflammation in depression: From evolutionary imperative to modern treatment target

Nature Reviews Immunology

Volumn 16, Issue 1, 2016, Pages 22-34

  Miller, Andrew H ^a   Raison, Charles L ^b  

^a EMORY UNIVERSITY   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CYTOKINE; INFLAMMASOME; NEUROTRANSMITTER; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS;

ADAPTIVE IMMUNITY; AVOIDANCE BEHAVIOR; BRAIN; DEPRESSION; HOST RESISTANCE; HUMAN; IMMUNE SYSTEM; INFLAMMATION; NONHUMAN; PREDATOR; PRIORITY JOURNAL; REVIEW; RISK; STRESS; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; PATHOLOGY; PSYCHOLOGY; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ADAPTIVE IMMUNITY; BRAIN; CYTOKINES; DEPRESSION; HUMANS; IMMUNITY, INNATE; INFLAMMASOMES; INFLAMMATION; NEUROTRANSMITTER AGENTS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84952342629     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri.2015.5     Document Type: Review

References (129)

1. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990 2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 386, 743-800 (2015).
2. Rush A. J., et al. Acute and longer-Term outcomes in depressed outpatients requiring one or several treatment steps: a STAR D report. Am. J. Psychiatry. 163, 1905-1917 (2006).
3. Pace T. W., et al. Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am. J. Psychiatry. 163, 1630-1633 (2006).
4. Bierhaus A., et al. A mechanism converting psychosocial stress into mononuclear cell activation. Proc. Natl Acad. Sci. USA. 100, 1920-1925 (2003).
5. Aschbacher K., et al. Maintenance of a positive outlook during acute stress protects against pro-inflammatory reactivity and future depressive symptoms. Brain Behav. Immun. 26, 346-352 (2012).
6. Raison C. L., & Miller A. H. The evolutionary significance of depression in Pathogen Host Defense (PATHOS D). Mol. Psychiatry. 18, 15-37 (2013).
7. Watson P. J., & Andrews P. W. Toward a revised evolutionary adaptationist analysis of depression: the social navigation hypothesis. J. Affect. Disord. 72, 1-14 (2002).
8. Kinney D. K., & Tanaka M. An evolutionary hypothesis of depression and its symptoms, adaptive value, and risk factors. J. Nerv. Ment. Dis. 197, 561-567 (2009).
9. Slavich G. M., & Irwin M. R. From stress to inflammation and major depressive disorder: a social signal transduction theory of depression. Psychol. Bull. 140, 774-815 (2014).
10. Seedat S., et al. Cross-national associations between gender and mental disorders in the World Health Organization World Mental Health Surveys. Arch. Gen. Psychiatry. 66, 785-795 (2009).
11. Moieni M., et al. Sex differences in depressive and socioemotional responses to an inflammatory challenge: implications for sex differences in depression. Neuropsychopharmacology. 40, 1709-1716 (2015).
12. Udina M., et al. Interferon-induced depression in chronic hepatitis C: a systematic review and meta-Analysis. J. Clin. Psychiatry. 73, 1128-1138 (2012).
13. Raison C. L., Lowry C. A., & Rook G. A. Inflammation, sanitation, and consternation: loss of contact with coevolved, tolerogenic microorganisms and the pathophysiology and treatment of major depression. Arch. Gen. Psychiatry. 67, 1211-1224 (2010).
14. Rook G. A., Lowry C. A., & Raison C. L. Hygiene and other early childhood influences on the subsequent function of the immune system. Brain Res. 1617, 47-62 (2015).
15. Yirmiya R., et al. Illness, cytokines, and depression. Ann. NY Acad. Sci. 917, 478-487 (2000).
16. Miller A. H., Maletic V., & Raison C. L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry. 65, 732-741 (2009).
17. Maes M. Major depression and activation of the inflammatory response system. Adv. Exp. Med. Biol. 461, 25-46 (1999).
18. Brambilla P., et al. Increased M1/decreased M2 signature and signs of Th1/Th2 shift in chronic patients with bipolar disorder, but not in those with schizophrenia. Transl Psychiatry 4, e406 (2014).
19. Drago A., Crisafulli C., Calabro M., & Serretti A. Enrichment pathway analysis. The inflammatory genetic background in bipolar disorder. J. Affect Disord. 179, 88-94 (2015).
20. Mostafavi S., et al. Type I interferon signaling genes in recurrent major depression: increased expression detected by whole-blood RNA sequencing. Mol. Psychiatry 19,1267-1274 (2013).
21. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog. Neuropsychopharmacol. Biol. Psychiatry. 19, 11-38 (1995).
22. Bufalino C., Hepgul N., Aguglia E., & Pariante C. M. The role of immune genes in the association between depression and inflammation: a review of recent clinical studies. Brain Behav. Immun. 31, 31-47 (2012).
23. Capuron L., et al. Neurobehavioral effects of interferon-α in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology. 26, 643-652 (2002).
24. Reichenberg A., et al. Cytokine-Associated emotional and cognitive disturbances in humans. Arch. Gen. Psychiatry. 58, 445-452 (2001).
25. Bonaccorso S., et al. Increased depressive ratings in patients with hepatitis C receiving interferon-α- based immunotherapy are related to interferon-α- induced changes in the serotonergic system. J. Clin. Psychopharmacol. 22, 86-90 (2002).
26. Harrison N. A., et al. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol. Psychiatry. 66, 407-414 (2009).
27. Tyring S., et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 367, 29-35 (2006).
28. Abbott R., et al. Tumour necrosis factor-α inhibitor therapy in chronic physical illness: a systematic review and meta-Analysis of the effect on depression and anxiety. J. Psychosom. Res. 79, 175-84 (2015).
29. Kohler O., et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-Analysis of randomized clinical trials. JAMA Psychiatry. 71, 1381-1391 (2014).
30. Raison C. L., et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 70 31-41 (2013).
31. Miller A. H., & Raison C. L. Are anti-inflammatory therapies viable treatments for psychiatric disorders?: where the rubber meets the road. JAMA Psychiatry. 72, 527-528 (2015).
32. Michopoulos V., et al. Association of CRP genetic variation and CRP level with elevated PTSD symptoms and physiological responses in a civilian population with high levels of trauma. Am. J. Psychiatry. 172, 353-362 (2015).
33. Fernandes B. S., et al. C reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-Analysis and implications. Mol. Psychiatry http://dx.doi.org/10.1038/mp.2015.87 (2015).
34. Morris S. E., & Cuthbert B. N. Research Domain Criteria: cognitive systems, neural circuits, and dimensions of behavior. Dialogues Clin. Neurosci. 14, 29-37 (2012).
35. Miller A. H., Haroon E., Raison C. L., & Felger J. C. Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depress. Anxiety. 30, 297-306 (2013).
36. Cattaneo A., et al. Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline predictors and longitudinal targets. Neuropsychopharmacology. 38, 377-385 (2013).
37. Eurelings L. S., Richard E., Eikelenboom P., van Gool W. A., & Moll van Charante E. P. Low-grade inflammation differentiates between symptoms of apathy and depression in community-dwelling older individuals. Int. Psychogeriatr. 27, 639-647 (2015).
38. Pearson T. A., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 107, 499-511 (2003).
39. Irwin M. R., & Cole S. W. Reciprocal regulation of the neural and innate immune systems. Nat. Rev. Immunol. 11, 625-632 (2011).
40. Iwata M., Ota K. T., & Duman R. S. The inflammasome: pathways linking psychological stress, depression, and systemic illnesses. Brain Behav. Immun. 31, 105-114 (2013).
41. Strowig T., Henao-Mejia J., Elinav E., & Flavell R. Inflammasomes in health and disease. Nature. 481, 278-286 (2012).
42. Fleshner M. Stress-evoked sterile inflammation, danger associated molecular patterns (DAMPs), microbial associated molecular patterns (MAMPs) and the inflammasome. Brain Behav. Immun. 27, 1-7 (2013).
43. Cox S. S., et al. Adrenergic and glucocorticoid modulation of the sterile inflammatory response. Brain Behav. Immun. 36, 183-192 (2014).
44. Pan Y., Chen X. Y., Zhang Q. Y., & Kong L. D. Microglial NLRP3 inflammasome activation mediates IL 1β related inflammation in prefrontal cortex of depressive rats. Brain Behav. Immun. 41, 90-100 (2014).
45. Zhang Y., et al. NLRP3 inflammasome mediates chronic mild stress-induced depression in mice via neuroinflammation. Int. J. Neuropsychopharmacol. 18, pii: pyv006 (2015).
46. Paugh S. W., et al. NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. Nat. Genet. 47, 607-614 (2015).
47. Rhen T., & Cidlowski J. A. Antiinflammatory action of glucocorticoidsnew mechanisms for old drugs. N. Engl. J. Med. 353, 1711-1723 (2005).
48. Raison C. L., & Miller A. H. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am. J. Psychiatry. 160, 1554-1565 (2003).
49. Pace T. W., Hu F., & Miller A. H. Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav. Immun. 21, 9-19 (2007).
50. Alcocer-Gomez E., et al. NLRP3 inflammasome is activated in mononuclear blood cells from patients with major depressive disorder. Brain Behav. Immun. 36, 111-117 (2014).
51. Stertz L., et al. Damage-Associated molecular patterns and immune activation in bipolar disorder. Acta Psychiatr. Scand. 132, 211-217 (2015).
52. Rawdin B. J., et al. Dysregulated relationship of inflammation and oxidative stress in major depression. Brain Behav. Immun. 31, 143-152 (2013).
53. Maes M., Galecki P., Chang Y. S., & Berk M. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog. Neuropsychopharmacol. Biol. Psychiatry. 35, 676-692 (2011).
54. Mayer E. A., Knight R., Mazmanian S. K., Cryan J. F., & Tillisch K. Gut microbes and the brain: paradigm shift in neuroscience. J. Neurosci. 34, 15490-15496 (2014).
55. Maslanik T., et al. Commensal bacteria and MAMPs are necessary for stress-induced increases in IL 1β and IL 18 but not IL 6, IL 10 or MCP 1. PLoS ONE 7, e50636 (2012).
56. Lyte M., Vulchanova L., & Brown D. R. Stress at the intestinal surface: catecholamines and mucosa-bacteria interactions. Cell Tissue Res. 343, 23-32 (2011).
57. Rao J. S., Harry G. J., Rapoport S. I., & Kim H. W. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol. Psychiatry. 15, 384-392 (2010).
58. Steiner J., et al. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J. Psychiatr. Res. 42, 151-157 (2008).
59. Torres-Platas S. G., Cruceanu C., Chen G. G., Turecki G., & Mechawar N. Evidence for increased microglial priming and macrophage recruitment in the dorsal anterior cingulate white matter of depressed suicides. Brain Behav. Immun. 42, 50-59 (2014).
60. Nagy C., et al. Astrocytic abnormalities and global DNA methylation patterns in depression and suicide. Mol. Psychiatry. 20, 320-328 (2015).
61. Setiawan E., et al. Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry. 72, 268-275 (2015).
62. Hannestad J., et al. The neuroinflammation marker translocator protein is not elevated in individuals with mild to moderate depression: a [11C]PBR28 PET study. Brain Behav. Immun. 33, 131-138 (2013).
63. Sandiego C. M., et al. Imaging robust microglial activation after lipopolysaccharide administration in humans with PET. Proc. Natl Acad. Sci. USA. 112, 12468-12473 (2015).
64. Quan N., & Banks W. A. Brain-immune communication pathways. Brain Behav. Immun. 21, 727-735 (2007).
65. DMello C., Le T., & Swain M. G. Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factor-α signaling during peripheral organ inflammation. J. Neurosci. 29, 2089-2102 (2009).
66. Hennessy E., Griffin E. W., & Cunningham C. Astrocytes are primed by chronic neurodegeneration to produce exaggerated chemokine and cell infiltration responses to acute stimulation with the cytokines IL 1β and TNF-α. J. Neurosci. 35, 8411-8422 (2015).
67. Wohleb E. S., et al. β-Adrenergic receptor antagonism prevents anxiety-like behavior and microglial reactivity induced by repeated social defeat. J. Neurosci. 31 6277-6288 (2011).
68. Wohleb E. S., Powell N. D., Godbout J. P., & Sheridan J. F. Stress-induced recruitment of bone marrow-derived monocytes to the brain promotes anxiety-like behavior. J. Neurosci. 33, 13820-13833 (2013).
69. Krugel U., Fischer J., Radicke S., Sack U., & Himmerich H. Antidepressant effects of TNF-α blockade in an animal model of depression. J. Psychiatr. Res. 47, 611-616 (2013).
70. Arends S., et al. Baseline predictors of response and discontinuation of tumor necrosis factor-α blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res. Ther. 13, R94 (2011).
71. Gillespie C. F., Garlow S. J., Binder E. B., Schatzberg A. F., & Nemeroff C. B. in Textbook of Psychopharmacology (eds Schatzberg A. F., & Nemeroff C. B.) 903-944 (America Psychiatric Publishing, 2009).
72. Zhu C. B., et al. Interleukin 1 receptor activation by systemic lipopolysaccharide induces behavioral despair linked to MAPK regulation of CNS serotonin transporters. Neuropsychopharmacology. 35, 2510-2520 (2010).
73. Neurauter G., et al. Chronic immune stimulation correlates with reduced phenylalanine turnover. Curr. Drug Metab. 9, 622-627 (2008).
74. Felger J. C., et al. Tyrosine metabolism during interferon-α administration: association with fatigue and CSF dopamine concentrations. Brain Behav. Immun. 31, 153-160 (2013).
75. Maes M., Leonard B. E., Myint A. M., Kubera M., & Verkerk R. The new 5 HT hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3 dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry. 35, 702-721 (2011).
76. Raison C. L., et al. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-α: relationship to CNS immune responses and depression. Mol. Psychiatry. 15, 393-403 (2010).
77. Steiner J., et al. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission?. J. Neuroinflamm. 8, 94 (2011).
78. Tavares R. G., et al. Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes. Neurochem. Int. 40, 621-627 (2002).
79. Tilleux S., & Hermans E. Neuroinflammation and regulation of glial glutamate uptake in neurological disorders. J. Neurosci. Res. 85, 2059-2070 (2007).
80. Hardingham G. E., Fukunaga Y., & Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat. Neurosci. 5, 405-414 (2002).
81. Koo J. W., Russo S. J., Ferguson D., Nestler N. J., & Duman R. S. Nuclear factor ?B is a critical mediator of stress-impaired neurogenesis and depressive behavior. Proc. Natl Acad. Sci. USA. 107, 2669-2674 (2010).
82. Goshen I., et al. Brain interleukin 1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol. Psychiatry. 13, 717-728 (2008).
83. Haroon E., et al. IFN-α-induced cortical and subcortical glutamate changes assessed by magnetic resonance spectroscopy. Neuropsychopharmacology. 39, 1777-1785 (2014).
84. Haroon E., et al. Conceptual convergence:increased inflammation is associated with increased basal ganglia glutamate in patients with major depression. Mol. Psychiatry http://dx.doi.org/10.1038/.mp.2015.206 (2015).
85. Walker A. K., et al. NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL/6J mice. Neuropsychopharmacology. 38, 1609-1616 (2013).
86. OConnor J. C., et al. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3 dioxygenase activation in mice. Mol. Psychiatry. 14, 511-522 (2009).
87. Duman R. S., & Monteggia L. M. A neurotrophic model for stress-related mood disorders. Biol. Psychiatry. 59, 1116-1127 (2006).
88. Hodes G. E., et al. Individual differences in the peripheral immune system promote resilience versus susceptibility to social stress. Proc. Natl Acad. Sci. USA. 111, 16136-16141 (2014).
89. Capuron L., et al. Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon-α administration. Arch. Gen. Psychiatry. 69, 1044-1053 (2012).
90. Eisenberger N. I., et al. Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward. Biol. Psychiatry. 68, 748-754 (2010).
91. Felger J. C., et al. Chronic interferon-α decreases dopamine 2 receptor binding and striatal dopamine release in association with anhedonia-like behavior in nonhuman primates. Neuropsychopharmacology. 38, 2179-2187 (2013).
92. Dowell N. G., et al. Acute changes in striatal microstructure predict the development of interferon-α induced fatigue. Biol. Psychiatry http://dx.doi.org/.10.1016/j.biopsych.2015.05.015 (2015).
93. Harrison N. A., Cercignani M., Voon V., & Critchley H. D. Effects of inflammation on hippocampus and substantia nigra responses to novelty in healthy human participants. Neuropsychopharmacology. 40, 831-838 (2015).
94. Harrison N. A., et al. A neuro-computational account of how inflammation enhances sensitivity to punishments versus rewards. Biol. Psychiatry http://dx.doi.org/10.1016/j.biopsych.2015.07.018 (2015).
95. Felger J. C., et al. Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression. Mol. Psychiatry http://dx.doi.org/10.1038/mp.2015.168 (2015).
96. Harrison N. A., et al. Neural origins of human sickness in interoceptive responses to inflammation. Biol. Psychiatry. 66, 415-422 (2009).
97. Slavich G. M., Way B. M., Eisenberger N. I., & Taylor S. E. Neural sensitivity to social rejection is associated with inflammatory responses to social stress. Proc. Natl Acad. Sci. USA. 107, 14817-14822 (2010).
98. Eisenberger N. I., & Lieberman M. D. Why rejection hurts: a common neural alarm system for physical and social pain. Trends Cogn. Sci. 8, 294-300 (2004).
99. Muscatell K. A., et al. Greater amygdala activity and dorsomedial prefrontal-Amygdala coupling are associated with enhanced inflammatory responses to stress. Brain Behav. Immun. 43, 46-53 (2015).
100. Gimeno D., et al. Associations of C reactive protein and interleukin 6 with cognitive symptoms of depression: 12 year follow up of the Whitehall II study. Psychol. Med. 39, 413-423 (2009).
101. Au B., Smith K. J., Gariepy G., & Schmitz N. The longitudinal associations between C reactive protein and depressive symptoms: evidence from the English Longitudinal Study of Ageing (ELSA). Int. J. Geriatr. Psychiatry. 30, 976-984 (2015).
102. Duivis H. E., et al. Depressive symptoms, health behaviors, and subsequent inflammation in patients with coronary heart disease: prospective findings from the heart and soul study. Am. J. Psychiatry. 168, 913-920 (2011).
103. Baumeister D., Akhtar R., Ciufolini S., Pariante C. M., & Mondelli V. Childhood trauma and adulthood inflammation: a meta-Analysis of peripheral C reactive protein, interleukin 6 and tumour necrosis factor-α. Mol. Psychiatry http://dx.doi.org/10.1038/.mp.2015.67 (2015).
104. Danese A., Pariante C. M., Caspi A., Taylor A., & Poulton R. Childhood maltreatment predicts adult inflammation in a life-course study. Proc. Natl Acad. Sci. USA. 104, 1319-1324 (2007).
105. Tartter M., Hammen C., Bower J. E., Brennan P. A., & Cole S. Effects of chronic interpersonal stress exposure on depressive symptoms are moderated by genetic variation at IL6 and IL1β in youth. Brain Behav. Immun. 46, 104-111 (2015).
106. Klengel T., et al. Allele-specific FKBP5 DNA demethylation mediates gene-childhood trauma interactions. Nat. Neurosci. 16, 33-41 (2013).
107. Miller G. E., et al. A functional genomic fingerprint of chronic stress in humans: blunted glucocorticoid and increased NF ?B signaling. Biol. Psychiatry. 64, 266-272 (2008).
108. Brachman R. A., Lehmann M. L., Maric D., & Herkenham M. Lymphocytes from chronically stressed mice confer antidepressant-like effects to naive mice. J. Neurosci. 35, 1530-1538 (2015).
109. Lewitus G. M., Cohen H., & Schwartz M. Reducing post-Traumatic anxiety by immunization. Brain Behav. Immun. 22, 1108-1114 (2008).
110. Lewitus G. M., et al. Vaccination as a novel approach for treating depressive behavior. Biol. Psychiatry. 65, 283-288 (2009).
111. Derecki N. C., et al. Regulation of learning and memory by meningeal immunity: a key role for IL 4. J. Exp. Med. 207, 1067-1080 (2010).
112. Louveau A., et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 523, 337-341 (2015).
113. Kim S. J., et al. CD4+CD25+ regulatory T cell depletion modulates anxiety and depression-like behaviors in mice. PLoS ONE 7, e42054 (2012).
114. Rosas-Ballina M., et al. Acetylcholine-synthesizing T cells relay neural signals in a vagus nerve circuit. Science. 334, 98-101 (2011).
115. Bauer M. E., et al. Dexamethasone-induced effects on lymphocyte distribution and expression of adhesion molecules in treatment-resistant depression. Psychiatry Res. 113, 1-15 (2002).
116. Wang X., Wu H., & Miller A. H. Interleukin 1α (IL 1α) induced activation of p38 mitogen-Activated protein kinase inhibits glucocorticoid receptor function. Mol. Psychiatry. 9, 65-75 (2004).
117. Wei J., Zhang M., & Zhou J. Myeloid-derived suppressor cells in major depression patients suppress T cell responses through the production of reactive oxygen species. Psychiatry Res. 228, 695-701 (2015).
118. van Deventer H. W., et al. The inflammasome component NLRP3 impairs antitumor vaccine by enhancing the accumulation of tumor-Associated myeloid-derived suppressor cells. Cancer Res. 70, 10161-10169 (2010).
119. Li Y., et al. Altered expression of CD4+CD25+ regulatory T cells and its 5 HT1a receptor in patients with major depression disorder. J. Affect. Disord. 124, 68-75 (2010).
120. Williamson L. L., et al. Got worms?. Perinatal exposure to helminths prevents persistent immune sensitization and cognitive dysfunction induced by early-life infection. Brain Behav. Immun. (2015).
121. Olofsson P. S., Rosas-Ballina M., Levine Y. A., & Tracey K. J. Rethinking inflammation: neural circuits in the regulation of immunity. Immunol. Rev. 248, 188-204 (2012).
122. Wang Y., Chen X., Cao W., & Shi Y. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat. Immunol. 15, 1009-1016 (2014).
123. Warner-Schmidt J. L., Vanover K. E., Chen E. Y., Marshall J. J., & Greengard P. Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc. Natl Acad. Sci. USA. 108, 9262-9267 (2011).
124. Gurven M., & Kaplan H. Longevity among hunter-gatherers: a cross-cultural examination. Popul. Dev. Rev. 33, 321-365 (2007).
125. Fumagalli M., et al. Signatures of environmental genetic adaptation pinpoint pathogens as the main selective pressure through human evolution. PLoS Genet. 7, e1002355 (2011).
126. Kuningas M., et al. Selection for genetic variation inducing pro-inflammatory responses under adverse environmental conditions in a Ghanaian population. PLoS ONE 4, e7795 (2009).
127. Ratcliffe M. A bad case of the flu?: the comparative phenomenology of depression and somatic illness. J. Conscious. Studies. 20, 198-218 (2013).
128. Marin I., & Kipnis J. Learning and memory and the immune system. Learn. Mem. 20, 601-606 (2013).
129. Mehta D., et al. Transcriptional signatures related to glucose and lipid metabolism predict treatment response to the tumor necrosis factor antagonist infliximab in patients with treatment-resistant depression. Brain Behav. Immun. 31, 205-215 (2013).